(Q37035294)

17 August 2017

1 reference

title

Old and emerging therapies in chronic hepatitis C: an update (English)

1 reference

17 August 2017

1 reference

1 reference

1 reference

M Deutsch

1

1 reference

PubMed ID

18088238

17 August 2017

S J Hadziyannis

series ordinal

2

1 reference

17 August 2017

1 January 2008

1 reference

Journal of Viral Hepatitis

17 August 2017

1 reference

17 August 2017

15

1 reference

17 August 2017

2-11

1 reference

17 August 2017

1

1 reference

Emerging treatments in chronic hepatitis B.

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

New and modified interferon alfas: preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Re-treatment of chronic hepatitis C with consensus interferon .

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Oligonucleotide-based strategies to inhibit human hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00887.X

10.1111/J.1365-2893.2007.00887.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18088238